<DOC>
	<DOCNO>NCT02075619</DOCNO>
	<brief_summary>This open-label , single-centre , randomize , single dose , three-way crossover , six sequence study evaluate comparative bioavailability two Fixed Dose Combination ( FDC ) tablet formulation amlodipine rosuvastatin relative innovator sample fast condition , healthy adult subject . Subjects 12 Chinese 12 Caucasian subject live Singapore . The randomisation stratify ethnicity ensure equal number subject assign dose sequence . Subjects receive follow three treatment administer randomized three-way crossover design : reference treatment consist single 10mg amlodipine tablet 20mg rosuvastatin tablet ; single fix dose combination tablet consist 10mg amlodipine 20mg rosuvastatin ( Test Formulation - FDC 1 ) ; another single fix dose combination tablet consist 10mg amlodipine 20mg rosuvastatin ( Test Formulation - FDC 2 ) . Two test formulation active pharmaceutical ingredient ( amlodipine rosuvastatin ) , dose different inactive ingredient . Each subject participate three treatment period . The study consist screen phase , three treatment period follow-up visit . The three treatment period separate washout period 12-17 day .</brief_summary>
	<brief_title>Relative Bioavailability Study One Amlodipine 10mg Tablet One Rosuvastatin 20mg Tablet Two Fixed Dose Combinations Amlodipine ( 10mg ) Rosuvastatin ( 20mg ) Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female 21 65 year age inclusive , time signing informed consent . Alanine transaminase , alkaline phosphatase total bilirubin &lt; =1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Normal electrocardiogram ( ECG ) morphology measurement . Single correct QT interval ( QTc ) &lt; 450 millisecond ( msec ) . In particular QTc &lt; 450 msec QT &lt; 480 msec subject Bundle Branch Block base average three ECGs obtain brief recording period . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter / specifically list inclusion exclusion criterion , outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; definition , `` document '' refers outcome Investigator 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( MIU/mL ) estradiol &lt; 40 picograms per milliliter ( pg/mL ) ( &lt; 147 picomole per liter ) confirmatory ] ; On hormone replacement therapy ( HRT ) whose menopausal status doubt require use protocol approve contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ; Childbearing potential negative pregnancy test determine serum urine human chorionic gonadotropin ( hCG ) test screen prior dose agrees use one contraception method appropriate period time ( determined product label Investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 14 day last dose amlodipine/rosuvastatin , i.e . single dose treatment period 3 . Male subject female partner childbearing potential must agree use one contraceptive method donate sperm . These criterion must follow time first dose study medication followup contact visit . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 18.5 29.9 kilogram per square meter ( kg/m^2 ) ( inclusive ) . Chinese Caucasian selfreported subject parent 4 grandparent . The ethnic group define National Registration Identity Cards provide additional confirmation ethnicity . Capable give write informed consent , include compliance requirement restriction list consent form . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study . More 2 standard drink day woman , 3 drink day ( 30 gram [ g ] alcohol ) man , 4 day per week . One standard drink contain 10g pure alcohol equivalent beer ( 220 milliliter [ mL ] ) , 1 glass wine ( 100mL ) , 1 nip ( 30mL ) spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A systolic blood pressure &lt; 95 millimeter mercury ( mmHg ) recent history postural symptom . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug /alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Pregnant female determine positive urine hCG test Day 1 serum hCG screen visit . Where participation study would result donation blood blood product excess 450mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice ( and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ) 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Amlodipine</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Dyslipidaemia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hypertension</keyword>
</DOC>